Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Signaling cascades transmit information downstream and upstream but unlikely simultaneously.

Catozzi S, Di-Bella JP, Ventura AC, Sepulchre JA.

BMC Syst Biol. 2016 Aug 25;10(1):84. doi: 10.1186/s12918-016-0303-2.

2.

MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1.

Shi L, Zhang B, Sun X, Lu S, Liu Z, Liu Y, Li H, Wang L, Wang X, Zhao C.

Br J Cancer. 2014 Dec 9;111(12):2316-27. doi: 10.1038/bjc.2014.580. Epub 2014 Nov 20.

3.

Dealing with diversity in computational cancer modeling.

Johnson D, McKeever S, Stamatakos G, Dionysiou D, Graf N, Sakkalis V, Marias K, Wang Z, Deisboeck TS.

Cancer Inform. 2013 May 7;12:115-24. doi: 10.4137/CIN.S11583. Print 2013.

4.

An integrated computational/experimental model of lymphoma growth.

Frieboes HB, Smith BR, Chuang YL, Ito K, Roettgers AM, Gambhir SS, Cristini V.

PLoS Comput Biol. 2013;9(3):e1003008. doi: 10.1371/journal.pcbi.1003008. Epub 2013 Mar 28.

5.

Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.

Thurber GM, Yang KS, Reiner T, Kohler RH, Sorger P, Mitchison T, Weissleder R.

Nat Commun. 2013;4:1504. doi: 10.1038/ncomms2506.

6.

Integrated experimental and model-based analysis reveals the spatial aspects of EGFR activation dynamics.

Shankaran H, Zhang Y, Chrisler WB, Ewald JA, Wiley HS, Resat H.

Mol Biosyst. 2012 Nov;8(11):2868-82. doi: 10.1039/c2mb25190f. Epub 2012 Sep 5.

7.

Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors.

van de Ven AL, Wu M, Lowengrub J, McDougall SR, Chaplain MA, Cristini V, Ferrari M, Frieboes HB.

AIP Adv. 2012 Mar;2(1):11208. Epub 2012 Mar 22.

8.

Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivity.

Wynn ML, Ventura AC, Sepulchre JA, GarcĂ­a HJ, Merajver SD.

BMC Syst Biol. 2011 Oct 4;5:156. doi: 10.1186/1752-0509-5-156.

9.

Long signaling cascades tend to attenuate retroactivity.

Ossareh HR, Ventura AC, Merajver SD, Del Vecchio D.

Biophys J. 2011 Apr 6;100(7):1617-26. doi: 10.1016/j.bpj.2011.02.014.

10.

Exploiting clinical trial data drastically narrows the window of possible solutions to the problem of clinical adaptation of a multiscale cancer model.

Stamatakos GS, Georgiadi EC, Graf N, Kolokotroni EA, Dionysiou DD.

PLoS One. 2011 Mar 3;6(3):e17594. doi: 10.1371/journal.pone.0017594.

11.

Physical oncology: a bench-to-bedside quantitative and predictive approach.

Frieboes HB, Chaplain MA, Thompson AM, Bearer EL, Lowengrub JS, Cristini V.

Cancer Res. 2011 Jan 15;71(2):298-302. doi: 10.1158/0008-5472.CAN-10-2676. Epub 2011 Jan 11. Review. Erratum in: Cancer Res. 2011 Mar 1;71(5):2024.

12.

Nonlinear modelling of cancer: bridging the gap between cells and tumours.

Lowengrub JS, Frieboes HB, Jin F, Chuang YL, Li X, Macklin P, Wise SM, Cristini V.

Nonlinearity. 2010;23(1):R1-R9.

13.

Predictions of tumour morphological stability and evaluation against experimental observations.

Pham K, Frieboes HB, Cristini V, Lowengrub J.

J R Soc Interface. 2011 Jan 6;8(54):16-29. doi: 10.1098/rsif.2010.0194. Epub 2010 Jun 2.

Supplemental Content

Support Center